Delivery Order SPE2DR25D1103-SPE2DR26FE403
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $3,608.26 on December 11, 2025, for 100-count tablets of Envarsus XR 4 mg, with completion targeted for January 5, 2026. This competitively awarded, firm fixed-price delivery order leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,358.64 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 0.75 mg tablets (100 count) on November 18, 2025, with an ultimate completion date of December 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $2,037.96 delivery order to AmerisourceBergen Drug Corp on December 16, 2025, for the supply of Envarsus XR 0.75 mg tablets (100-count units). This firm fixed-price delivery order, with an ultimate completion date of January 8, 2026, represents a competitively awarded contract with no set-aside designation. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,035.60 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 1 mg tablets (30-count packaging). This competitively awarded, non-set-aside contract utilizes firm fixed price pricing and is scheduled for completion by June 23, 2025. The order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vehicle running...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 10, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) with a ceiling value of $3,608.26. This is a firm fixed-price delivery order with no set-aside designation, placing performance in Conshohocken, Pennsylvania, and scheduled for completion by December 3, 2025. The award represents a competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $1,718.48 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 1 mg tablets (100-count units) on August 7, 2025, with completion expected by August 28, 2025. This firm fixed price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's Corporate Office division, with performance to be executed from the company's Conshohocken, Pennsylvania headquarters. The contract falls under...
- The Defense Logistics Agency awarded a delivery order valued at $3,608.26 to AmerisourceBergen Drug Corp on December 15, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units). This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by January 7, 2026, with performance to be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,711.94 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 4 mg tablets (100-count) on October 21, 2025, with completion targeted for November 12, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,165.05 to AmerisourceBergen Drug Corp for 30 tablets of Envarsus XR 1 mg on July 29, 2025, with an ultimate completion date of August 19, 2025. This firm fixed price delivery order carries no set-aside designation and represents a competitively awarded transaction under the company's larger indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 4 mg with a ceiling value of $9,020.65. This order, awarded on December 17, 2025, represents a firm fixed price delivery under a non-set-aside competitive procurement process. The pharmaceutical product will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with an ultimate completion date of January 9, 2026. This delivery order is...
- SPE2DR25D1103Indefinite Delivery Contract
- SPE2DR25D1103-SPE2DR26FE403Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,358.25 to AmerisourceBergen Drug Corp for Envarsus XR 1 mg tablets (100-count supply) on December 16, 2025, with an ultimate completion date of January 8, 2026. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated as SPE2DX, valued at $999,999,999.00 and extending through December 2026. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement supporting military and veteran healthcare systems. As the prime contractor on the SPE2DX IDC, the company supplies a comprehensive range of pharmaceutical products including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This delivery order for Envarsus XR—a tacrolimus-based immunosuppressant medication—represents one of numerous small-to-large value transactions executed under this comprehensive global pharmaceutical support vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 12/15/25 |